BroadOak Capital Partners
BroadOak Capital Partners is a privately held, life-sciences-focused boutique financial institution founded in 2006, providing growth capital (via BroadOak Asset Management) and M&A/capital-raising advisory (via BroadOak Partners) to commercial-stage companies in life sciences tools, diagnostics, and biopharma services.
- Company typePrivate
- Founded2006
- HeadquartersBethesda, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BroadOak Capital Partners does
BroadOak Capital Partners, founded in 2006 by Bill Snider and Lars Hanan, is a privately held boutique financial institution exclusively focused on the life sciences industry. Operating from offices in Bethesda (DC metro), San Francisco, and Raleigh (Research Triangle), the firm provides two integrated services through distinct regulated entities: BroadOak Asset Management (SEC-registered investment adviser) delivers direct growth capital to commercial-stage life sciences companies, while BroadOak Partners (FINRA/SIPC broker-dealer) provides M&A advisory, capital raising, and strategic advisory services. The firm invests across three subsectors — life sciences tools ($130B market), diagnostics ($50B), and biopharma services ($100B) — and often serves as the first institutional investor in portfolio companies, leveraging flexible deal structures with no minimum investment threshold to serve companies underserved by traditional financial institutions.
The firm has built a diversified capital platform comprising seven investment funds and six special purpose vehicles, with over $300M in total capital deployed across 75+ portfolio companies and 50+ advised M&A transactions since inception. Recent platform expansion includes the BioTools Venture Fund (launched October 2022 with DeciBio Consulting, focused on pre-commercialization biotools and cell/gene therapy), the BroadOak Income Fund (a private credit vehicle, final closing March 2025), Fund VI (initial closing June 2025), and a $200M+ permanent capital base added in October 2025 alongside Research Corporation Technologies. Revenue is generated through investment management fees, transaction-based advisory fees, and carried interest from investment vehicles; pricing is negotiated per transaction and not publicly disclosed. Distribution is relationship-driven — direct outreach, industry events (annual BroadOak Investor Days, BioTools Innovator, Phacilitate Advanced Therapies Week), and an entrepreneur inquiry form — supplemented by three US offices and a European BD presence (UK-based VP Pete Corish).
The firm is owned by its principals, with leadership including five Partners (Bill Snider, D. Kyle Wilson, Tim Johnson, Lars Hanan, Matt McFarland), three Operating Partners with PhD scientific backgrounds (Anup Parikh, Aaron Goldman, Trent Carrier), three Managing Directors, and a team of ~17 across investment, advisory, and operations. Recent strategic activity includes the $40M debt refinancing of Harvard Bioscience (December 2025) with a board seat for Bill Snider, the launch of Codis as a global CDMO (October 2025), advisory on the Enzo Biochem take-private and Scientific Industries Genie divestiture, and continued co-investment activity in portfolio companies such as Codis, Pluristyx, PAK BioSolutions, and PBS Biotech.
BroadOak Capital Partners firmographics
Firmographics- Name
- BroadOak Capital Partners
- Legal name
- BroadOak Partners, LLC
- Website
- https://broadoak.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BroadOak Capital Partners is a privately held, life-sciences-focused boutique financial institution founded in 2006, providing growth capital (via BroadOak Asset Management) and M&A/capital-raising advisory (via BroadOak Partners) to commercial-stage companies in life sciences tools, diagnostics, and biopharma services.
- Ownership category
- akta.pro rank
BroadOak Capital Partners industry classification
Industry- Product category
- Life Sciences Investment Banking
- NAICS
- Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Corporate Finance & Capital Advisory (BPAHADAB)
- akta.pro secondary industry
- Multi-Sector / Generalist Growth Equity (FSANACAO)
Keywords
Where BroadOak Capital Partners is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BroadOak Capital Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Investment Management (BroadOak Asset Management): BroadOak provides direct growth capital investments to life sciences companies. Returns come from equity appreciation, dividends, and exits through M&A or other liquidity events. The firm manages multiple funds including Fund VI, BroadOak Income Fund, and special purpose vehicles, with over $200M in permanent capital added in 2025.
- Investment Banking Advisory (BroadOak Partners): BroadOak Partners provides M&A advisory, sell-side and buy-side advisory, equity/debt/mezzanine capital raising, leveraged transactions, valuations, and strategic financial advisory services. Revenue is generated through transaction fees and success-based compensation.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
BroadOak Capital Partners product offering
Product offeringCore offering
BroadOak Capital Partners is a boutique financial institution that provides growth capital and investment banking advisory services to life sciences companies. Through BroadOak Asset Management, it invests directly in commercial-stage life sciences tools, diagnostics, and biopharma services companies; through BroadOak Partners (FINRA/SIPC broker-dealer), it provides M&A advisory, capital raising, and strategic financial advisory services to the same sector.
Product overview
BroadOak Capital Partners is a life sciences focused boutique financial institution operating two core divisions: BroadOak Asset Management provides direct growth capital investments to commercial-stage life sciences companies, while BroadOak Partners offers investment banking advisory services including M&A, capital markets, and strategic advisory. The firm supports companies across the life sciences tools, diagnostics, and biopharma services sectors. BroadOak complements its core offerings with the BioTools Innovator accelerator program, the BioTools Venture Fund (early-stage growth capital in partnership with DeciBio), the BroadOak Income Fund (private credit for mature companies), and Fund VI (growth capital fund family). Since 2006, the firm has invested in more than 70 companies and advised on over 50 successful M&A transactions.
Differentiator
Problem solved
Functional benefit
Products and services
- BroadOak Asset Management (Growth Capital Investing)
- BroadOak Partners (Investment Banking Advisory)
- BioTools Venture Fund
- BroadOak Income Fund
- BroadOak Fund VI
- BioTools Innovator Accelerator Program
Quantifiable outcome
- 120+ life sciences companies partnered with over 15 years
- +3 more outcomes
Companies that use BroadOak Capital Partners
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
BroadOak Capital Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BroadOak Capital Partners partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Guggenheim SecuritiesminorGuggenheim Securities served as lead financial advisor to Harvard Bioscience in connection with the $40 million debt refinancing transaction with BroadOak.
- DeciBio ConsultingcoreBroadOak partnered with DeciBio Consulting to launch the BioTools Venture Fund in October 2022. DeciBio provides strategy consulting and market intelligence serving clients across the precision medicine ecosystem. Together, they provide early-stage growth capital and mentorship to promising young companies in the biotools space with a focus on cell and gene therapy.
- BioTools InnovatorcoreBroadOak is a founding sponsor of BioTools Innovator, the world's premier nonprofit accelerator and competition for life science tools and diagnostic companies. The program provides early-stage companies with educational materials, networking opportunities, exposure to key stakeholders, and funding and mentorship. BroadOak has been a proud sponsor since the program began in 2020.
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
BroadOak Capital Partners competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Customer concentration
BroadOak Capital Partners social profiles
Digital presenceBroadOak Capital Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
BroadOak Capital Partners leadership team
Management profileNumber of profiles
Profiles14 records
BroadOak Capital Partners subsidiaries and ownership
Company hierarchySubsidiaries2 records
BroadOak Capital Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BroadOak Capital Partners M&A and investment
M&A and investmentM&A2 records
Investments34 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BroadOak Capital Partners
What does BroadOak Capital Partners do?
BroadOak Capital Partners is a boutique financial institution that provides growth capital and investment banking advisory services to life sciences companies. Through BroadOak Asset Management, it invests directly in commercial-stage life sciences tools, diagnostics, and biopharma services companies; through BroadOak Partners (FINRA/SIPC broker-dealer), it provides M&A advisory, capital raising, and strategic financial advisory services to the same sector.
Is BroadOak Capital Partners a public or private company?
BroadOak Capital Partners is a private company. It is classified as management employee owned and is currently operating.
When was BroadOak Capital Partners founded?
BroadOak Capital Partners was founded in 2006. It employs 11 to 50 people.
Where is BroadOak Capital Partners based?
BroadOak Capital Partners is headquartered in Bethesda, United States, in the North America region.
How does BroadOak Capital Partners make money?
Two revenue lines are on record. Investment Management (BroadOak Asset Management) is the primary driver. The others are investment Banking Advisory (BroadOak Partners).
Does BroadOak Capital Partners have an API?
No public API is recorded for BroadOak Capital Partners.
What industry is BroadOak Capital Partners in?
BroadOak Capital Partners's product category is Life Sciences Investment Banking. Its primary akta.pro industry code is BPAHADAB, Corporate Finance & Capital Advisory, with a secondary code of FSANACAO, Multi-Sector / Generalist Growth Equity. Its NAICS code is 52394 and its SIC code is 6282.